Last reviewed · How we verify
SB213503 lot 1
SB213503 is a selective antagonist of the chemokine receptor CCR3, which blocks eosinophil recruitment and activation in inflammatory airway diseases.
SB213503 is a selective antagonist of the chemokine receptor CCR3, which blocks eosinophil recruitment and activation in inflammatory airway diseases. Used for Asthma with eosinophilic phenotype, Eosinophilic airway inflammation.
At a glance
| Generic name | SB213503 lot 1 |
|---|---|
| Also known as | GSK Biologicals combined diphteria, tetanus, acellular pertussis and inactivated poliovirus lot 1 vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | CCR3 antagonist |
| Target | CCR3 |
| Modality | Biologic |
| Therapeutic area | Respiratory / Immunology |
| Phase | Phase 3 |
Mechanism of action
CCR3 is highly expressed on eosinophils and plays a central role in their migration to sites of inflammation. By antagonizing CCR3, SB213503 reduces eosinophil infiltration into airways and tissues, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly relevant in eosinophilic airway diseases where eosinophil accumulation drives pathology.
Approved indications
- Asthma with eosinophilic phenotype
- Eosinophilic airway inflammation
Common side effects
- Headache
- Upper respiratory tract infection
- Nasopharyngitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB213503 lot 1 CI brief — competitive landscape report
- SB213503 lot 1 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI